JP2018503618A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018503618A5 JP2018503618A5 JP2017533836A JP2017533836A JP2018503618A5 JP 2018503618 A5 JP2018503618 A5 JP 2018503618A5 JP 2017533836 A JP2017533836 A JP 2017533836A JP 2017533836 A JP2017533836 A JP 2017533836A JP 2018503618 A5 JP2018503618 A5 JP 2018503618A5
- Authority
- JP
- Japan
- Prior art keywords
- vedolizumab
- therapeutic agent
- patient
- concentration
- serum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021024874A JP7530314B2 (ja) | 2014-12-24 | 2021-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
| JP2024022738A JP2024069231A (ja) | 2014-12-24 | 2024-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462096636P | 2014-12-24 | 2014-12-24 | |
| US62/096,636 | 2014-12-24 | ||
| US201562117750P | 2015-02-18 | 2015-02-18 | |
| US62/117,750 | 2015-02-18 | ||
| US201562132917P | 2015-03-13 | 2015-03-13 | |
| US62/132,917 | 2015-03-13 | ||
| PCT/US2015/000476 WO2016105572A1 (en) | 2014-12-24 | 2015-12-23 | PREDICTING OUTCOME OF TREATMENT WITH AN ANTI-α4β7 INTEGRIN ANTIBODY |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021024874A Division JP7530314B2 (ja) | 2014-12-24 | 2021-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018503618A JP2018503618A (ja) | 2018-02-08 |
| JP2018503618A5 true JP2018503618A5 (enExample) | 2019-02-07 |
| JP6904905B2 JP6904905B2 (ja) | 2021-07-21 |
Family
ID=56151288
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017533836A Active JP6904905B2 (ja) | 2014-12-24 | 2015-12-23 | 抗α４β７インテグリン抗体による治療の結果の予測 |
| JP2021024874A Active JP7530314B2 (ja) | 2014-12-24 | 2021-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
| JP2024022738A Pending JP2024069231A (ja) | 2014-12-24 | 2024-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021024874A Active JP7530314B2 (ja) | 2014-12-24 | 2021-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
| JP2024022738A Pending JP2024069231A (ja) | 2014-12-24 | 2024-02-19 | 抗α４β７インテグリン抗体による治療の結果の予測 |
Country Status (4)
| Country | Link |
|---|---|
| US (3) | US20170360926A1 (enExample) |
| EP (1) | EP3237004B1 (enExample) |
| JP (3) | JP6904905B2 (enExample) |
| WO (1) | WO2016105572A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| AU2012253422B2 (en) | 2011-05-10 | 2015-08-13 | Société des Produits Nestlé S.A. | Methods of disease activity profiling for personalized therapy management |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| US9862760B2 (en) | 2015-09-16 | 2018-01-09 | Novartis Ag | Polyomavirus neutralizing antibodies |
| JP7069032B2 (ja) | 2016-03-24 | 2022-05-17 | ミレニアム ファーマシューティカルズ， インコーポレイテッド | がん免疫治療における胃腸の免疫関連有害事象の治療方法 |
| US10918716B2 (en) | 2016-05-04 | 2021-02-16 | Millennium Pharmaceuticals, Inc. | Triple combination therapy for treating Crohn's disease |
| EP3468597A1 (en) | 2016-06-12 | 2019-04-17 | Millennium Pharmaceuticals, Inc. | Method of treating inflammatory bowel disease |
| WO2018104893A1 (en) * | 2016-12-06 | 2018-06-14 | Glaxosmithkline Intellectual Property Development Limited | Alpha4-beta7 antibodies with incrased fcrn binding and/or half-life |
| BR112019024875A2 (pt) * | 2017-05-26 | 2020-06-16 | Millennium Pharmaceuticals, Inc. | Métodos para o tratamento da ileíte do reservatório crônica |
| EP3612843A1 (en) | 2017-05-31 | 2020-02-26 | Prometheus Biosciences, Inc. | Methods for assessing mucosal healing in crohn's disease patients |
| KR20200069333A (ko) * | 2017-10-10 | 2020-06-16 | 프로메테우스 바이오사이언시즈, 인크. | 베돌리주맙 치료를 모니터링하는 방법 |
| WO2019147824A1 (en) | 2018-01-26 | 2019-08-01 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a pde4 inhibitor |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| US20230033021A1 (en) | 2018-06-20 | 2023-02-02 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an integrin inhibitor |
| US20210363233A1 (en) | 2018-06-20 | 2021-11-25 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an il-12/il-23 inhibitor |
| US20230312700A1 (en) | 2018-06-20 | 2023-10-05 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a tnf inhibitor |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246273A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with a jak or other kinase inhibitor |
| WO2020117795A1 (en) * | 2018-12-04 | 2020-06-11 | Prometheus Biosciences, Inc. | Assessment and monitoring of mucosal healing in children and adults with crohn's disease |
| BR112022025020A2 (pt) * | 2020-06-12 | 2023-02-14 | Vera Therapeutics Inc | Dosagem de anticorpos neutralizantes de poliomavírus |
| CN114974595A (zh) * | 2022-05-13 | 2022-08-30 | 江苏省人民医院（南京医科大学第一附属医院） | 一种克罗恩病患者黏膜愈合预测模型及方法 |
| WO2024249568A1 (en) | 2023-05-30 | 2024-12-05 | Paragon Therapeutics, Inc. | Alpha4beta7 integrin antibody compositions and methods of use |
| CN121889424A (zh) | 2023-08-14 | 2026-04-17 | 派拉冈医疗公司 | α4β7整联蛋白结合蛋白及使用方法 |
| WO2025101973A1 (en) * | 2023-11-09 | 2025-05-15 | Cedars-Sinai Medical Center | Systems and methods for disease classification and treatment recommendation using large language models |
| WO2026058045A1 (en) | 2024-09-12 | 2026-03-19 | Takeda Pharmaceutical Company Limited | Alpha4beta7 inhibitor and il-23 inhibitor combination therapy |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| WO1996024673A1 (en) | 1995-02-10 | 1996-08-15 | Leukosite, Inc. | Mucosal vascular addressins and uses thereof |
| US7803904B2 (en) | 1995-09-01 | 2010-09-28 | Millennium Pharmaceuticals, Inc. | Mucosal vascular addressing and uses thereof |
| US7147851B1 (en) | 1996-08-15 | 2006-12-12 | Millennium Pharmaceuticals, Inc. | Humanized immunoglobulin reactive with α4β7 integrin |
| US6197582B1 (en) | 1998-03-18 | 2001-03-06 | The Trustees Of Columbia University In The City Of New York | Development of human monoclonal antibodies and uses thereof |
| US20010046496A1 (en) | 2000-04-14 | 2001-11-29 | Brettman Lee R. | Method of administering an antibody |
| AU2004283065B2 (en) | 2003-05-22 | 2009-11-26 | Metaproteomics, Llc | Anti-inflammatory pharmaceutical compositions for reducing inflammation and the treatment or prevention of gastric toxicity |
| EP1948691A1 (en) | 2005-11-17 | 2008-07-30 | Millennium Pharmaceuticals, Inc. | HUMANIZED IMMUNOGLOBULIN REACTIVE WITH a4ß7INTEGRIN |
| JP2012507723A (ja) | 2008-11-03 | 2012-03-29 | シェーリング コーポレイション | 炎症性腸疾患生物マーカーおよび関連治療方法 |
| RU2016127812A (ru) | 2011-03-31 | 2018-12-06 | Дженентек, Инк. | Способы введения антагонистов интегрина бета7 |
| MX367097B (es) | 2011-05-02 | 2019-08-05 | Millennium Pharm Inc | FORMULACION PARA ANTICUERPO ANTI-A4ß7. |
| UA116189C2 (uk) | 2011-05-02 | 2018-02-26 | Мілленніум Фармасьютікалз, Інк. | КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА |
| WO2016086147A1 (en) | 2014-11-26 | 2016-06-02 | Millennium Pharmaceuticals, Inc. | Vedolizumab for the treatment of fistulizing crohn's disease |
| CA2916283C (en) | 2015-01-09 | 2024-07-02 | Pfizer Inc. | MADCAM ANTAGONIST DOSING REGIMEN |
-
2015
- 2015-12-23 WO PCT/US2015/000476 patent/WO2016105572A1/en not_active Ceased
- 2015-12-23 JP JP2017533836A patent/JP6904905B2/ja active Active
- 2015-12-23 EP EP15873834.4A patent/EP3237004B1/en not_active Revoked
- 2015-12-23 US US15/538,869 patent/US20170360926A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/455,103 patent/US11596688B2/en active Active
-
2021
- 2021-02-19 JP JP2021024874A patent/JP7530314B2/ja active Active
-
2023
- 2023-01-18 US US18/156,279 patent/US20240173402A1/en active Pending
-
2024
- 2024-02-19 JP JP2024022738A patent/JP2024069231A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018503618A5 (enExample) | ||
| Agarwal et al. | Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial) | |
| Abegunde et al. | Preventive health measures in inflammatory bowel disease | |
| Kapetanovic et al. | Antibody response is reduced following vaccination with 7‐valent conjugate pneumococcal vaccine in adult methotrexate‐treated patients with established arthritis, but not those treated with tumor necrosis factor inhibitors | |
| Kaur et al. | A randomised, single-blind, single-dose, three-arm, parallel-group study in healthy subjects to demonstrate pharmacokinetic equivalence of ABP 501 and adalimumab | |
| JP7057360B2 (ja) | 抗－ｃｄ３抗体製剤 | |
| Tsai et al. | Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience | |
| ES2456043T3 (es) | Receptor soluble del activador de plasminógeno de tipo uroquinasa (suPAR) como marcador predictivo de enfermedades cardiovasculares | |
| Vogtländer et al. | Impaired response rates, but satisfying protection rates to influenza vaccination in dialysis patients | |
| WO2021226402A1 (en) | Progestogen formulations for use in modulating a cytokine storm mediator | |
| Wei et al. | Bacteria expressed hepatitis E virus capsid proteins maintain virion-like epitopes | |
| JP2014114288A5 (enExample) | ||
| JP2015529199A5 (enExample) | ||
| CY1116874T1 (el) | Δοσολογικο σχημα για τη χορηγηση ενος cd19xcd3 αμφιειδικου αντισωματος | |
| Post et al. | Efficiency of placental transfer of vaccine-elicited antibodies relative to prenatal Tdap vaccination status | |
| Pfeifer et al. | Effect of Ritonavir on 99mTechnetium–Mebrofenin Disposition in Humans: A Semi‐PBPK Modeling and In Vitro Approach to Predict Transporter‐Mediated DDIs | |
| Ignatyev et al. | Experimental study on the possibility of treatment of some hemorrhagic fevers | |
| JP2012502103A5 (enExample) | ||
| JP2019519544A5 (enExample) | ||
| JP2018516244A5 (enExample) | ||
| EP4384270A1 (en) | Treatment of atopic dermatitis | |
| Bongiovanni et al. | Evaluation of the immune response to COVID-19 vaccine mRNA BNT162b2 and correlation with previous COVID-19 infection | |
| Haruna et al. | Local production of broadly cross‐reactive IgE against multiple fungal cell wall polysaccharides in patients with allergic fungal rhinosinusitis. | |
| Cetkovska et al. | Childhood pemphigus associated with montelukast administration. | |
| Ghazaiean et al. | Ebselen: A promising therapy protecting cardiomyocytes from excess iron in iron-overloaded thalassemia patients |